
Chemical and Pharmaceutical Bulletin p. 1486 - 1493 (1992)
Update date:2022-08-04
Topics:
Yamanaka
Suda
Kabasawa
Kawamura
Ogawa
Sawada
Ohhara
Structural modification of the cardiotonic agent, loprinone (E-1020, 1), suggested by data that it has a less positive chronotropic effect than milrinone (15), led us to find novel bradycardic agents that were structurally different from homoveratryl amine derivatives. Alkyl-oxy, -thio, and -amino derivatives at the 2-position of the pyridine ring of 1 produced bradycardic activity without a significant effect on blood pressure and myocardial contractility. Aryloxy analogues also decreased beart rate, and members with an electron-withdrawing group at the ortho position of the phenyl ring showed higher activity. Replacement of the imidazo[1,2-a]pyridine with pyridine resulted in diminished activity. The mechanism of bradycardic activity of these compounds seems to be direct action on the sinus node.
View MoreAngelisun(Chongqing) Pharmaceutical Co., LTD.
Contact:+86-23-68030926-816
Address:D1-7 Tech & Entrepreneurs Park, Kecheng Road, Erlang Hi-Tech Areas, Chongqing, China
Dongtai Xinyuan Chemical Co., Ltd.
Contact:+86-21-56733000
Address:404F, 99Nong No.117 Zhongtan Rd. Shanghai
Jiangsu Feymer Technology Co., Ltd.
Contact:+86-512-58110132
Address:Fenghuang Town, Zhangjiagang City, Jiangsu Province, China
Contact:+86-0311-84455288-844
Address:Mayu Industrial Park, Jinzhou, Hebei, China.
Improve Medical Technology(Nanxiong) Co., Ltd
Contact:86-751-3836997
Address:No.33, Pingan First Road, Fine Chemical Industry Base, Nanxiong City, Shaoguan, Guangdong, China
Doi:10.1021/ol401276b
(2013)Doi:10.1080/00304948.2013.786587
(2013)Doi:10.1016/S0022-1139(98)00310-8
(1999)Doi:10.1021/ja00050a030
(1992)Doi:10.1002/anie.201209109
()Doi:10.1016/S0040-4020(01)88306-X
(1992)